1. Generics Bulletin
  2. >>Business

Strides' US Revenues Soar As Recovery Strategy Is ‘Executing To Plan’

 
• By Penelope MacRae

Strides Pharma is “very confident” about future after the Indian company’s fourth-quarter US revenues rocketed by 181% and EBITDA margins beat market expectations.

Steps
STRIDES' US REVENUES GROW SHARPLY • Source: Shutterstock

After posting strong fourth-quarter earnings, Strides Pharma Science Ltd founder and group chief executive Arun Kumar said the company’s fortunes "are now resurgent" thanks to a “major strategy reset” focused on growing US revenues and an exit from Australia.

US sales rocketed 181% to INR37.32bn ($53m) in the fiscal fourth-quarter of 2018-19 from the same year-ago period, while overall...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Teva’s Ratiopharm Bags Rights In Germany To Formycon’s Stelara Biosimilar

 
• By Dean Rudge

Teva’s subsidiary in Germany plans to begin rolling out a biosimilar to Stelara in the third quarter of this year after shaking hands on a distribution agreement with manufacturer Formycon.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

More from Generics Bulletin